Table 1.
Small-molecule modulators of the spliceosome in ongoing cancer clinical trials (access date: October 2021).
| Trial Identifier (ClinicalTrials.gov) | Phase | Status | Patient Characteristics | Drug and Treatment Regimen | Target |
|---|---|---|---|---|---|
| NCT03573310 | 1 | Active, not recruiting | Advanced solid tumors, NHL, or lower risk MDS | JNJ-64619178 (po) monotherapy | PRMT5 |
| NCT02783300 | 1 | Recruiting | Advanced solid tumors and non-Hodgkin lymphoma | GSK3326595 (po) monotherapy; part 3 includes in combination with pembrolizumab | PRMT5 |
| NCT03854227 | 1 | Recruiting | Advanced or metastatic solid tumors | PF-06939999 (po) alone or in combination with docetaxel | PRMT5 |
| NCT04089449 | 1 | Recruiting | Advanced solid tumors and high-grade gliomas | PRT811 (po) monotherapy | PRMT5 |
| NCT03886831 | 1 | Recruiting | Advanced solid tumors and hematologic malignancies | PRT543 monotherapy | PRMT5 |
| NCT03666988 | 1 | Completed | Advanced solid tumors and diffuse large B cell lymphoma | GSK3368715 monotherapy | PRMT1 |
| NCT028`41540 | 1/2 | Recruiting | Myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia | H3B-8800 monotherapy | SF3B |
| NCT03614728 | 1/2 | Recruiting | Myelodysplastic syndromes and acute myeloid leukemia | GSK3326595 monotherapy | PRMT5 |